Full-Time

Immunology Sales Specialist

Nephrology

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$101k - $145k/yr

+ Bonus

Nashville, TN, USA

Remote

Local travel and some overnight travel are required.

Bachelor's, Associate's

Category
Sales & Account Management (1)
Required Skills
Sales

Get referred to Mallinckrodt

See people who can refer or advise you

Requirements
  • A Bachelor's degree and at least 3 years of experience in nephrology are required.
  • In lieu of a Bachelor's degree, an Associate's degree and at least 5 years of experience, or at least 7 years of successful pharmaceutical or industry-equivalent experience in nephrology, will be considered.
  • A valid motor vehicle operator's license is required.
  • Strong clinical and disease-state knowledge is required for clinical selling and decision-making.
  • Knowledge of industry trends, economic sectors, and market dynamics is required to drive strategy.
  • The ability to build new business and expand existing customer relationships profitably is required.
  • The ability to identify resources and solve problems using available information and support resources is required.
Responsibilities
  • Meet or exceed territory sales-plan and expense-plan goals by developing and implementing strategies for the assigned territory.
  • Establish and maintain professional relationships with targeted opinion leaders and physicians.
  • Maintain current working knowledge of company products and relevant disease states.
  • Develop territory business plans, plan workdays and weeks, establish call plans, and prepare for sales calls.
  • Develop and implement special territory programs, including speakers' bureau programs and symposia, to maximize sales opportunities.
  • Develop and maintain permanent customer records.
  • Complete assigned administrative tasks in a timely, accurate, legible, and organized manner.
  • Communicate current, effective, and accurate sales presentations to customers.
  • Maintain a professional sales image in all business matters.
  • Perform duties in compliance with applicable regulations, pharmaceutical guidelines, and company policies and procedures.
  • Attend regional and national conferences throughout the year.
  • Travel locally and occasionally overnight as required.
Desired Qualifications
  • Current experience within the territory and customer knowledge are highly preferred.
  • Experience selling biologics to specialty physicians in rare-disease areas is preferred.

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Get referred to Mallinckrodt

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 12, 2026 guidance reaffirmed $1.94 billion to $2.00 billion sales.
  • First-quarter 2026 sales reached $468 million, up $261 million year over year.
  • Keenova booked $23 million merger synergies and targets $150 million annual run-rate savings.

What critics are saying

  • Opioid litigation still shadows the business after 2023 and 2025 bankruptcies.
  • Integration failure or synergy misses would damage 2026 EBITDA guidance and NYSE listing plans.
  • Another leverage shock or adverse court ruling could force a third restructuring.

What makes Mallinckrodt unique

  • Acthar Gel and XIAFLEX anchor Keenova's branded specialty franchise in 2026.
  • July 31, 2025 Endo merger created a larger U.S.-focused therapeutics platform.
  • Christiana Stamoulis joined September 22, 2025 to drive M&A and corporate development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

StockTitan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.